BioAdaptives, Inc. (OTC: BDPT) has detailed the scientific strategy behind its Xcellara cellular wellness platform as it prepares for the commercial launch of XcellaraHeart on August 1. The platform combines a stem/progenitor cell mobilization base, supported by a human randomized controlled trial that demonstrated an average 268.8% increase in circulating stem/progenitor-type cells, with tissue-specific ingredients designed to support the body’s natural signaling pathways and direct those cells to targeted areas.
XcellaraHeart, the platform’s first commercial application, pairs the Xcellara base with Tanshinone IIA, a compound derived from Danshen that has been studied for its role in cardiovascular SDF-1α/CXCR4 signaling. BioAdaptives plans to expand the platform with additional formulas targeting wellness categories including joint mobility, skin health, cognitive wellness, and metabolic resilience, following the same supply-and-direction development model.
The company’s flagship Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial showing a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications.
The complete scientific evidence dossier for the XcellaraHeart formulation will be available at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara base from published research on Tanshinone IIA and from the company’s product-development rationale for combining the two.
This announcement is important because it provides insight into the company’s strategic approach to cellular wellness, which could have implications for the dietary supplement industry and consumers seeking science-based products for specific health concerns. The upcoming launch of XcellaraHeart represents a potential new option for cardiovascular support, leveraging a clinically validated stem cell mobilization base.
For more information about BioAdaptives, visit www.bioadaptives.com. To view the full press release, visit https://ibn.fm/YxZaA.
